

DIASORIN SUBMITS LIAISON PLEX[®] YEAST BLOOD CULTURE ASSAY FOR THE LIAISON PLEX[®] SYSTEM TO THE U.S. FDA

Saluggia, Italy – March 13, 2024 - Diasorin (FTSE MIB: DIA) announced today that it has applied for 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the LIAISON PLEX[®] Yeast Blood Culture Assay, the second molecular multiplexing panel on the LIAISON PLEX[®] analyzer.

The LIAISON PLEX[®] Yeast Blood Culture Assay represents the first of three multiplex blood culture panels for the microbiological diagnosis of bloodstream infections on the new LIAISON PLEX[®] system.

The assay allows the identification of pathogenic fungi commonly responsible for bloodstream infections. While observed less frequently than gram-positive or gram-negative bacteremia, the increasing prevalence of fungemia (presence of fungi or yeasts in the blood), such as *Candida auris*, are of great clinical concern.

Diasorin will continue to separate its blood culture panels for fungal infections from those for the identification of gram-positive and gram-negative bacteria in order to complement standard-of-care workflows and help reduce operational spending.

“The submission of the LIAISON PLEX Yeast Blood Culture Assay to the FDA rapidly follows the FDA clearance of the LIAISON PLEX System and the LIAISON PLEX Respiratory Flex Assay, demonstrating the commitment of Diasorin in bringing innovative solutions aligned with the molecular diagnostic market trends” said Angelo Rago, President of Luminex. *“This new blood culture panel will allow clinical laboratories and physicians to better address emerging clinical diagnostic needs, further strengthening our position in syndromic molecular testing”*.

About Diasorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, Diasorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 35 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions Diasorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at www.diasorin.com

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

INVESTOR RELATIONS

Riccardo Fava

Corporate VP Communication, ESG & Investor Relations
riccardo.fava@diasorin.com

Eugenia Ragazzo

Corporate Investor Relations & ESG Analyst
eugenia.ragazzo@diasorin.com